2020–2021 BCSC Basic and Clinical Science Course™
1 Update on General Medicine
Chapter 8: Hematologic Disorders
Alternate-day dosing of iron may yield greater absorption with fewer gastrointestinal adverse effects than a daily regimen in patients with iron deficiency anemia.
Allogeneic hematopoietic cell transplantation (HCT) is potentially curative in sickle cell disease and is strongly recommended for selected pediatric patients.
HCT may have a better than 90% cure rate for β-thalassemia when performed in a child with an HLA-identical sibling donor.
Edoxaban and betrixaban are 2 new factor Xa inhibitors recently approved for clinical use.
Idarucizumab is now available as an antidote for the thrombin inhibitor dabigatran; andexanet alfa has also been approved for reversal of rivaroxaban and apixaban.
Fostamatinib has recently received FDA approval for treatment of chronic idiopathic thrombocytopenic purpura (ITP).
Excerpted from BCSC 2020-2021 series: Section 1 - Update on General Medicine. For more information and to purchase the entire series, please visit https://www.aao.org/bcsc.